3652 results for «231»
3652 results
Stentless PCI, DCB and BVS in complex scenarios
20 May 2026 – From EuroPCR 2026
This session explores the use of stentless percutaneous coronary interventions (PCI) employing drug-coated balloons (DCB) and bioresorbable scaffolds (BVS) in complex coronary scenarios. Through detailed case discussions, it addresses decision-making processes, technical considerations, and practical tips for successfully completing PCI without permanent stenting.
DCB - Going beyond in-stent restenosis
20 May 2026 – From EuroPCR 2026
This session examines the expanding role of drug-coated balloons (DCB) beyond in-stent restenosis, including treatment of acute coronary syndromes, calcified lesions, and bifurcations. It reviews current evidence supporting DCB-based revascularization and outlines essential procedural steps to optimize outcomes.
New tools for risk stratification in STEMI
20 May 2026 – From EuroPCR 2026
This session highlights novel tools and scores for risk stratification in ST-elevation myocardial infarction (STEMI) patients. It covers prognostic indices such as the index of microcirculatory resistance, the PREDICT-STEMI score, thrombus characteristics, sex differences in outcomes, renal impairment impacts, and benefits of complete revascularization strategies.
How to achieve coronary patency during TAVI
21 May 2026 – From EuroPCR 2026
This session addresses techniques to achieve coronary artery patency during transcatheter aortic valve implantation (TAVI), highlighting advanced procedural approaches and management of high-risk anatomical scenarios.
Complications in coronary interventions
20 May 2026 – From EuroPCR 2026
This session reviews uncommon and challenging complications encountered during coronary interventions. Cases include brachial arteriovenous fistula following radial access, retained guidewires, coronary sinus perforation during device implantation, and complex atherectomy procedures, emphasizing preparedness and management strategies.
Sealing the deal: catheter based solutions for aortic disease
21 May 2026 – From EuroPCR 2026
Examine catheter-based solutions for aortic disease management, featuring innovative approaches to preserving branch vessels, managing vascular complications, and repairing challenging aneurysms with endografts and occluders.
Reliability and application of angio-based physiology in daily work
20 May 2026 – From EuroPCR 2026
This session evaluates the reliability and clinical application of angiography-based physiological assessments in daily practice. Topics include comparisons of angiography-derived microvascular resistance and flow metrics with invasive methods, reproducibility of quantitative flow ratio (QFR), and its correlation with symptom burden and other imaging modalities.
Various NSTEMI cases
21 May 2026 – From EuroPCR 2026
This session presents diverse NSTEMI case studies addressing complex diagnostic and interventional challenges, including coronary dissections, intramural hematomas, ischemic complications, and functional lesion assessment.
PCR Tokyo Valves 2026: Your travel guide featuring upcoming exclusive booking services and special deals.
Percutaneous or surgical management of post-infarction ventricular septal defects: The United Kingdom National Registry
17 Sep 2022
Elad Asher provides his take on the UK National Registry which was presented at the TCT congress 2022 by Joel Peter Giblett on behalf of the UK PIVSD investigators.
Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
EuroPCR 2026 – Long-term mortality following revascularisation for left main disease
20 May 2026
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a meta-analysis of long-term data from 4 randomised trials investigating...
